We’re excited to share that Biocytogen will be attending AET US on December 14-17 in San Diego, CA! Engage in insightful speakers, outstanding presentations and cutting-edge advancements at the exhibition. Have the opportunity to connect with scientists, researchers and industry leaders with in-depth discussions about the future innovations in therapeutics research and antibody discovery. Visit us at Booth #604 to learn more about our advancements in preclinical research with our fully human antibodies using our array of RenMice® platforms that play a key role in advancing therapeutic antibodies and biologics. Biocytogen is looking forward to supporting antibody drug development from preclinical research through IND-enabling studies. We hope to see you there!
What is AET US?
AET US (Antibody Engineering & Therapeutics) is a global, non-profit trade organization dedicated to supporting professionals and organizations engaged in antibody research and development. The Society actively collaborates with international agencies on critical scientific initiatives and plays a key role in advancing therapeutic innovation. The Antibody Engineering & Therapeutics conferences serve as premier global forums focused on the science and application of antibody and protein-based therapeutics. With in-depth scientific programs, cutting-edge engineering topics, interactive workshops, poster sessions, and extensive industry involvement, these events foster meaningful collaboration and drive progress in therapeutic development.
Event Overview
Date: December 14th-17th, 2025
Venue: Marriott Marquis San Diego Marina. 333 W Harbor Dr, San Diego, CA 92101
Event Schedule
For more information, please refer to AET Agenda
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We can’t wait to see you in San Diego, CA!
